Clinical Trial Update: Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations [Phase 1, Phase 2]

View source ↗

Summary

This update covers an ongoing Phase 1/2 study of amivantamab combined with tyrosine kinase inhibitors for advanced non-small cell lung cancer with ALK, ROS1, or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amivantamab (amivantamab)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Lung Cancer, Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING